Bristol-Myers Squibb Co vs Progressive Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Progressive Corp trades at $211.8 (market cap $123.45B). The key difference: Bristol-Myers Squibb Co and Progressive Corp are close in size by market cap, and Progressive Corp pays the higher dividend (6.55%). Which is the better fit depends on your goals.
| BMY | PGR | |
|---|---|---|
Market Cap | $129.94B | $123.45B |
Sector | Health | Financials |
52-Week High | $65.89 | $252.68 |
52-Week Low | $42.60 | $190.40 |
Enterprise Value | $163.92B | $131.66B |
Dividend Yield | 3.96% | 6.55% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →